N-{[5-(2-chlorophenyl)furan-2-yl]methyl}ethanamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-{[5-(2-chlorophenyl)furan-2-yl]methyl}ethanamine
• 英文别名: N-[[5-(2-chlorophenyl)furan-2-yl]methyl]ethanamine
• 化学式: C₁₃H₁₄ClNO
• mdl: MFCD08235428
• 分子量: 235.71
• InChiKey: METXPMNXLCHFES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  25.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Treatment of immunocompromised conditions with E-Selectin antagonist and G-CSF
  申请人：Mater Medical Research Institute

  公开号：EP2915539A1

  公开（公告）日：2015-09-09

  This invention discloses the use of an E-selectin antagonist and a mobilizer of hematopoietic stem cells or progenitor cells in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular relevant for prophylaxis and/or treatment of hematopoietic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.

  本发明公开了一种E-选择素拮抗剂和一种造血干细胞或祖细胞动员剂在治疗或预防因医疗导致的免疫功能低下病症的方法和组合物中的用途。本发明尤其适用于预防和/或治疗接受或拟接受针对快速分裂细胞或破坏细胞周期或细胞分裂的治疗的个体的造血疾病，包括中性粒细胞减少症、粒细胞减少症、贫血和血小板减少症。
• TREATMENT OF IMMUNOCOMPROMISED CONDITIONS WITH E-SELECTIN ANTAGONIST AND G-CSF
  申请人：Mater Medical Research Institute

  公开号：EP2249854B1

  公开（公告）日：2015-01-21
• TREATMENT AND PROPHYLAXIS
  申请人：Levesque Jean-Pierre

  公开号：US20110002881A1

  公开（公告）日：2011-01-06

  This invention discloses the use of an E-selectin antagonist in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular useful for prophylaxis and/or treatment of hematopoietic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.
• COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR
  申请人：THE UNIVERSITY OF QUEENSLAND

  公开号：US20160193294A1

  公开（公告）日：2016-07-07

  This invention discloses the use of an E-selectin antagonist and a mobilizer of hematopoietic stem cells or progenitor cells in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular relevant for prophylaxis and/or treatment of hematopoeitic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.
• US9254322B2
  申请人：——

  公开号：US9254322B2

  公开（公告）日：2016-02-09